Cardio Diagnostics Holdings, Inc Sponsors Becker’s Hospital Review 13th Annual Meeting

Cardio Diagnostics Holdings, Inc (NASDAQ: CDIO) today announced that it is sponsoring Becker’s Hospital Review 13th Annual Meeting. The conference is taking place next week, April 3-6, 2023, at the Hyatt Regency Hotel in Chicago. As part of Cardio Diagnostics’ sponsorship, the Company is further introducing their recently launched test, PrecisionCHD, at booth #300.

Becker’s Hospital Review conferences are among the healthcare industry’s leading events covering hospital leaders' business, operational and patient-centered concerns. This annual meeting will bring together over 420 elite hospital and health system executives.

Cardio Diagnostics’ mission is to help clinicians better detect and treat cardiovascular disease, the leading cause of death in the United States. At the core of its cardiovascular solutions is a proprietary Integrated Genetic-Epigenetic Engine™ created by company founders Meesha Dogan, Ph.D., and Robert Philibert, MD, Ph.D. This technology enables the development of a series of tests for precision prevention and early detection and assists in the personalized treatment of major types of cardiovascular diseases and associated co-morbidities including the already launched Epi+Gen CHD and PrecisionCHD tests. The company will also display Actionable Clinical Intelligence™, a platform for healthcare providers connecting the underlying DNA methylation and single nucleotide polymorphism biomarkers measured by this test to coronary heart disease (CHD).

"We are thrilled to sponsor Becker's Hospital Review 13th Annual Meeting and participate in this important event for hospital and health system executives," said Meesha Dogan, Ph.D., CEO of the Company. "This is a great opportunity to share our insights on how we are partnering with leading healthcare organizations to deploy our precision molecular cardiovascular medicine technologies that can bend the heart disease curve, help lower costs and improve patient care with a focus on our most recent product launched, PrecisionCHD."

About Cardio Diagnostics

Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for enabling improved prevention, early detection, and assists in the treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com.

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "should," "believe," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements include, without limitation, the Company’s expectations with respect to future performance, development and commercialization of products and services, the potential benefits and impact of the Company’s products and services, potential regulatory approvals, and the size and potential growth of current or future markets for the Company’s products and services. Forward-looking statements are statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties that could cause the actual results to differ materially from the expected results. These statements are based on various assumptions, whether or not identified in this press release, and are not intended to serve as, and they must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company’s product development and commercialization activities, including the degree that Epi+Gen CHD™ and PrecisionCHD™ tests are accepted and adopted by patients, healthcare professionals and participants in other key channels; the impact of COVID-19 on the Company’s business; economic conditions, dependence on management, dilution to stockholders, lack of capital, changes in laws or regulations, the effects of rapid growth upon the Company and the ability of management to execute our growth strategy and ability to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. Such factors could materially adversely affect the Company’s financial performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed within this press release.